Lifecore Biomedical Q1 revenue up 26% to $31.1M; Adjusted EBITDA turns positive at $3.1M

LIFECORE BIOMEDICAL, INC. DE

2026-Q1 EPS reported -$0.29 revenue$31,109,000

Revenue $31.1M (+26% YoY), driven by HA manufacturing (+$4.8M) and CDMO growth.
Net loss narrowed to $10.0M ($0.29 loss per share) from $16.2M ($0.53) a year ago.
Adjusted EBITDA of $3.1M vs negative $1.8M in prior year; SG&A down $5.9M.
Affirms transition period guidance: revenue $74-76M, Adjusted EBITDA $12-14M.
Signed 4 new programs (2 post-quarter); commercial site transfer with large pharma.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-25-000146
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2025-11-06T23:59:59+00:00
discovered_at: 2026-05-14T18:02:38.489903+00:00
generated_at: 2026-05-16T23:17:17.058759+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-25-000146
json_url: https://secwatch.observer/filing/0001005286-25-000146.json
markdown_url: https://secwatch.observer/filing/0001005286-25-000146.md
text_url: https://secwatch.observer/filing/0001005286-25-000146.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/0001005286-25-000146-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000146/lndc-20251106.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-25-000146

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.